Pharmacist support 24/7

Omvoh Mirikizumab IL23p19 Ulcerative Colitis Remission 2026

Author: Critical Kare PharmaGastroenterology & Biologics Desk

On November 17, 2026, gastroenterology panels presented updated long-term extension data confirming Omvoh® (Mirikizumab-mrkz 300 mg/15 mL IV infusion and 100 mg/mL subcutaneous prefilled pen) by Eli Lilly as a game-changing biological therapy for moderate-to-severe active ulcerative colitis (UC).

Targeting the p19 subunit of interleukin-23 with high affinity, Omvoh delivers sustained endoscopic mucosal healing, histopathological normalization, and rapid resolution of debilitating bowel urgency.

Through Critical Kare Pharma, certified genuine packs of Omvoh Mirikizumab IV and Subcutaneous Pen are accessible for specialty gastroenterology clinics and private patients worldwide via temperature-controlled logistics.

Omvoh Mirikizumab subcutaneous autoinjector and infusion solution in specialty pharmacy packaging

The LUCENT Clinical Program Benchmarks

  • Clinical Remission at Week 12: 24.2% of patients achieved rapid clinical remission during induction versus 13.3% on placebo.
  • Sustained One-Year Remission: In the maintenance phase, 49.9% of mirikizumab patients remained in steroid-free clinical remission at one year compared to 25.1% on placebo.
  • Bowel Urgency Relief: Up to 65% of patients reported complete or near-complete freedom from bowel urgency, an outcome strongly correlated with restoration of normal quality of life and vocational function.

Mechanism: Selective IL-23 Neutralization

Mirikizumab binds exclusively to the p19 subunit of human IL-23, neutralizing IL-23 without interacting with the p40 subunit shared by IL-12. This prevents Th17 cell expansion and halts down-stream secretion of pro-inflammatory cytokines IL-17A, IL-17F, and IL-22, dampening mucosal ulceration while preserving systemic Th1-mediated immune defenses.

Administration Regimen

Induction is delivered as 300 mg IV infusion at Weeks 0, 4, and 8, followed by maintenance dosing of 200 mg subcutaneously (two 100 mg injections) every 4 weeks. Sourced legally via Critical Kare Pharma under international physician prescriptions and cold-chain compliance (2°C–8°C).

Specialty Medicines

Omvoh Mirikizumab IL23p19 Ulcerative Colitis Remission 2026

C
Critical Kare PharmaGastroenterology & Biologics Desk
November 17, 2026—
Omvoh Mirikizumab IL23p19 Ulcerative Colitis Remission 2026
Critical Kare

At a glance

Evidence-informed overview from Critical Kare Pharma. Key themes in this article:

  • Clinically reviewed framing
  • Safety & protocol awareness
  • Patient-relevant takeaways

Prefer to chat on WhatsApp?

Message our pharmacy team directly about this treatment — we reply with product details, sourcing, and next steps.

Chat on WhatsApp

On November 17, 2026, gastroenterology panels presented updated long-term extension data confirming Omvoh® (Mirikizumab-mrkz 300 mg/15 mL IV infusion and 100 mg/mL subcutaneous prefilled pen) by Eli Lilly as a game-changing biological therapy for moderate-to-severe active ulcerative colitis (UC).

Targeting the p19 subunit of interleukin-23 with high affinity, Omvoh delivers sustained endoscopic mucosal healing, histopathological normalization, and rapid resolution of debilitating bowel urgency.

Through Critical Kare Pharma, certified genuine packs of Omvoh Mirikizumab IV and Subcutaneous Pen are accessible for specialty gastroenterology clinics and private patients worldwide via temperature-controlled logistics.

Omvoh Mirikizumab subcutaneous autoinjector and infusion solution in specialty pharmacy packaging

The LUCENT Clinical Program Benchmarks

  • Clinical Remission at Week 12: 24.2% of patients achieved rapid clinical remission during induction versus 13.3% on placebo.
  • Sustained One-Year Remission: In the maintenance phase, 49.9% of mirikizumab patients remained in steroid-free clinical remission at one year compared to 25.1% on placebo.
  • Bowel Urgency Relief: Up to 65% of patients reported complete or near-complete freedom from bowel urgency, an outcome strongly correlated with restoration of normal quality of life and vocational function.

Mechanism: Selective IL-23 Neutralization

Mirikizumab binds exclusively to the p19 subunit of human IL-23, neutralizing IL-23 without interacting with the p40 subunit shared by IL-12. This prevents Th17 cell expansion and halts down-stream secretion of pro-inflammatory cytokines IL-17A, IL-17F, and IL-22, dampening mucosal ulceration while preserving systemic Th1-mediated immune defenses.

Administration Regimen

Induction is delivered as 300 mg IV infusion at Weeks 0, 4, and 8, followed by maintenance dosing of 200 mg subcutaneously (two 100 mg injections) every 4 weeks. Sourced legally via Critical Kare Pharma under international physician prescriptions and cold-chain compliance (2°C–8°C).


C

Critical Kare PharmaGastroenterology & Biologics Desk

Consultants in inflammatory bowel disease biologics, mucosal immunology, interleukin pathway signaling, and international prescription logistics.

Continue your care journey

This article is for general education. For medicine availability, prescriptions, and orders, use our catalog and pharmacy team.

Chat on WhatsAppBrowse catalogTreatmentsContact pharmacistsUpload prescription

Related Articles

Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026

Specialty Medicines

Skyrizi Risankizumab Crohns Disease Ulcerative Colitis IBD 2026

Read Article

Found this helpful?